| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
|
29 |
S4 |
p. iv_vii
|
artikel
|
| 2 |
Appendix 1: Cancer of the Prostate: eUpdate published online 28 September 2017 (http://www.esmo.org/Guidelines/Genitourinary-Cancers/Cancer-of-the-Prostate)
|
|
|
|
29 |
S4 |
p. iv256
|
artikel
|
| 3 |
Appendix 2: Medullary Thyroid Cancer: eUpdate published online 19 February 2018 (http://www.esmo.org/Guidelines/Endocrine-and-Neuroendocrine-Cancers/Thyroid-cancer)
|
|
|
|
29 |
S4 |
p. iv257-iv258
|
artikel
|
| 4 |
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up † † Footnotes Approved by the ESMO Guidelines Committee, PaedCan and EURACAN: August 2018.
|
Casali, P.G.
|
|
|
29 |
S4 |
p. iv79-iv95
|
artikel
|
| 5 |
Corrections to “Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Marth, C.
|
|
|
29 |
S4 |
p. iv262
|
artikel
|
| 6 |
Corrections to “Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Hochhaus, A.
|
|
|
29 |
S4 |
p. iv261
|
artikel
|
| 7 |
Corrections to “Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Casali, P.G.
|
|
|
29 |
S4 |
p. iv267
|
artikel
|
| 8 |
Corrections to “Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines”
|
Aapro, M.
|
|
|
29 |
S4 |
p. iv271
|
artikel
|
| 9 |
Corrections to “Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines”
|
Roselló, S.
|
|
|
29 |
S4 |
p. iv260
|
artikel
|
| 10 |
Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|
Haanen, J.B.A.G.
|
|
|
29 |
S4 |
p. iv264-iv266
|
artikel
|
| 11 |
Corrections to “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Ledermann, J.A.
|
|
|
29 |
S4 |
p. iv259
|
artikel
|
| 12 |
Corrections to “Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Glynne-Jones, R.
|
|
|
29 |
S4 |
p. iv263
|
artikel
|
| 13 |
Corrections to “Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Casali, P.G.
|
|
|
29 |
S4 |
p. iv268-iv269
|
artikel
|
| 14 |
Corrections to “Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Kastritis, E.
|
|
|
29 |
S4 |
p. iv270
|
artikel
|
| 15 |
Delirium in adult cancer patients: ESMO Clinical Practice Guidelines † † Footnotes Approved by the ESMO Guidelines Committee: April 2018.
|
Bush, S.H.
|
|
|
29 |
S4 |
p. iv143-iv165
|
artikel
|
| 16 |
Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines † † Footnotes Approved by the ESMO Guidelines Committee: March 2018.
|
Larkin, P.J.
|
|
|
29 |
S4 |
p. iv111-iv125
|
artikel
|
| 17 |
Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines † † Footnotes Approved by the ESMO Guidelines Committee: April 2018.
|
Bossi, P.
|
|
|
29 |
S4 |
p. iv126-iv142
|
artikel
|
| 18 |
Editorial board
|
|
|
|
29 |
S4 |
p. ii-iii
|
artikel
|
| 19 |
ESMO Guidelines Committee
|
|
|
|
29 |
S4 |
p. iv_vi
|
artikel
|
| 20 |
ESMO Guidelines Committee Disclosures
|
|
|
|
29 |
S4 |
p. iv272-iv273
|
artikel
|
| 21 |
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up † † Footnotes Approved by the ESMO Guidelines Committee and EURACAN: December 2017.
|
Casali, P.G.
|
|
|
29 |
S4 |
p. iv68-iv78
|
artikel
|
| 22 |
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † † Footnotes Approved by the ESMO Guidelines Committee: August 2018.
|
Vogel, A.
|
|
|
29 |
S4 |
p. iv238-iv255
|
artikel
|
| 23 |
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † † Footnotes Approved by the ESMO Guidelines Committee: August 2002, last update December 2017. This publication supersedes the previously published version—Ann Oncol 2014; 25(Suppl 3): iii70–iii75.
|
Eichenauer, D.A.
|
|
|
29 |
S4 |
p. iv19-iv29
|
artikel
|
| 24 |
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines † † Footnotes Approved by the ESMO Guidelines Committee: October 2017.
|
Aapro, M.
|
|
|
29 |
S4 |
p. iv96-iv110
|
artikel
|
| 25 |
Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines † † Footnotes Approved by the ESMO Guidelines Committee: December 2004, last update April 2018. This publication supersedes the previously published version—Ann Oncol 2012; 23(Suppl 7): vii139–vii154.
|
Fallon, M.
|
|
|
29 |
S4 |
p. iv166-iv191
|
artikel
|
| 26 |
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † † Footnotes Approved by the ESMO Guidelines Committee: February 2002, last update September 2018. This publication supersedes the previously published version—Ann Oncol 2016; 27 (Suppl 5): v1–v27.
|
Planchard, D.
|
|
|
29 |
S4 |
p. iv192-iv237
|
artikel
|
| 27 |
Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † † Footnotes Approved by the ESMO Guidelines Committee: August 2008, last update December 2017. This publication supersedes the previously published version—Ann Oncol 2012; 23(Suppl 7): vii20–vii26.
|
Ray-Coquard, I.
|
|
|
29 |
S4 |
p. iv1-iv18
|
artikel
|
| 28 |
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † † Footnotes Approved by the ESMO Guidelines Committee: December 2006, last update January 2018. This publication supersedes the previously published version—Ann Oncol 2013; 24 (Suppl. 6): vi149–vi154.
|
Willemze, R.
|
|
|
29 |
S4 |
p. iv30-iv40
|
artikel
|
| 29 |
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up † † Footnotes Approved by the ESMO Guidelines Committee and EURACAN: December 2017.
|
Casali, P.G.
|
|
|
29 |
S4 |
p. iv51-iv67
|
artikel
|
| 30 |
Table of Contents
|
|
|
|
29 |
S4 |
p. v
|
artikel
|
| 31 |
Title Page
|
|
|
|
29 |
S4 |
p. iv
|
artikel
|
| 32 |
Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † † Footnotes Approved by the ESMO Guidelines Committee: October 2013, last update March 2018. This publication supersedes the previously published version—Ann Oncol 2013; 24(Suppl. 6): vi155–vi159.
|
Kastritis, E.
|
|
|
29 |
S4 |
p. iv41-iv50
|
artikel
|
Tijdschrift beschrijving